OBIO · Orchestra BioMed Holdings, Inc. · Metrics
$5.82
+0.17 (+3.01%)
At close · Oct 20
Return incl. dividend (before tax)
Market Cap
$339.59M
Shares
60.11M
Volume · Oct 20
992.78K
Avg daily vol (3M)
316.67K
OBIO metrics
78 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$5.82
Market cap
$339.59M
Price action
20 metricsPrice change (1W)
-4.4%
Price change (30D)
-9.6%
Price change (3M)
+52.3%
Price change (6M)
+29.9%
Price change (YTD)
+36.1%
Price change (1Y)
+70.2%
Trailing year
Price change (5Y)
-42.5%
52-week high
$6.35
52-week low
$3.49
Change from 52-week high
-11.0%
Change from 52-week low
+61.9%
Annualized volatility
65.4%
Annualized volatility (3M)
63.2%
Beta
1.5
RSI (14D)
48.2
Price vs SMA 50
+2.1%
Price vs SMA 200
+26.2%
Avg volume (3M)
303,543
Relative volume
0.8
Average dollar volume
$1.64M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
60.11M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
8.1×
reciprocal yield 12.3%
EV / EBITDA
—
EV / EBIT
—
P / sales
10.6×
reciprocal yield 9.4%
P / book
17.6
reciprocal yield 5.7%
FCF yield
-17.4%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-17.4%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
32.2×
reciprocal yield 3.1%
EV / revenue historical average (5Y)
32.2×
reciprocal yield 3.1%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
99.5%
Operating margin
-181.4%
Trailing 12 months
Net margin
-184.6%
Gross profit (TTM)
$31.82M
Operating profit (TTM)
−$57.99M
Net income (TTM)
−$59.03M
Trailing 12 months
Diluted EPS (TTM)
$-0.83
FCF margin
-184.8%
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-89.5%
Year over year
Net income growth YoY
—
Revenue (TTM)
$31.98M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+66.2%
Year over year · more shares
Revenue CAGR (3Y)
+111.6%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-305.5%
Return on assets
-51.0%
Debt / equity
0.4
Current ratio
8.3
EBITDA (TTM)
−$57.64M
Free cash flow (TTM)
−$59.10M
Quick ratio
8.2
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$79.40M
Latest balance sheet
Cash & equivalents
$20.47M
Total assets
$115.70M
Total debt
$15.00M
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$58.32M
Capital expenditures (TTM)
$781,000
R&D (TTM)
$63.22M
SG&A (TTM)
$26.59M
Stock compensation (TTM)
$11.12M
R&D / revenue
197.7%
Stock compensation / revenue
34.8%
Ownership (13F)
9 metrics13F filers
77
13F filer change QoQ
+12
Institutional ownership
46.1%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
30.7%
Private-fund adviser ownership
30.5%
Active holders' share change QoQ
+4.7%
Holder tenure
10.2
Price vs estimated holder cost
-38.6%
Ownership (registered funds)
1 metricsIndex-fund ownership
7.1%
Short interest
3 metricsShort interest
4.2%
Latest settlement · 7.0 days to cover
Days to cover
7.0d
Short-squeeze score
75 / 100
Insider activity
2 metricsNet insider buying (90D)
−$172,290
Insider-sentiment score
83 / 100
Risk flags
1 metricsGoing concern
—